搜索临床试验以:cALD HR-D(高风险,方案 D)
总计124个结果
-
National Opinion Research CenterCenters for Disease Control and Prevention; Emory Healthcare完全的
-
University of CopenhagenUniversity College Cork; University of Surrey完全的
-
Momenta Pharmaceuticals, Inc.终止
-
Augusta UniversityYale University; University of Alabama at Birmingham; Tufts University未知
-
Augusta UniversityYale University; University of Alabama at Birmingham; Tufts University未知
-
University of CopenhagenUniversity of Aarhus; Arla Foods; Arla Foods Ingredients完全的
-
Augusta University未知
-
University of Wisconsin, MadisonNational Institutes of Health (NIH); National Institute on Aging (NIA)完全的
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences, Ltd.; Fujian... 和其他合作者招聘中
-
Southwest Oncology GroupNational Cancer Institute (NCI)完全的
-
AHS Cancer Control Alberta终止
-
First Affiliated Hospital Xi'an Jiaotong University招聘中
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)完全的
-
King Faisal Specialist Hospital & Research Center未知
-
Assistance Publique - Hôpitaux de Paris完全的糖尿病肾病 | Persistent Proteinuria With Type II Diabetes法国
-
NPO Petrovax完全的
-
Guangdong Provincial People's HospitalFirst Affiliated Hospital, Sun Yat-Sen University; Henan Cancer Hospital; Dongguan People's Hospital 和其他合作者完全的
-
Spanish Lung Cancer GroupAventis Pharmaceuticals完全的
-
Boehringer Ingelheim终止艾滋病毒感染美国, 阿根廷, 巴西, 加拿大, 德国, 意大利, 西班牙